We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Hologic (HOLX) Outpaced the Stock Market Today
Read MoreHide Full Article
Hologic (HOLX - Free Report) closed at $71.19 in the latest trading session, marking a +1.17% move from the prior day. This change outpaced the S&P 500's 0.61% gain on the day. Meanwhile, the Dow gained 0.3%, and the Nasdaq, a tech-heavy index, added 1.28%.
The medical device maker's stock has dropped by 3.18% in the past month, falling short of the Medical sector's gain of 1.64% and the S&P 500's gain of 2.08%.
The investment community will be paying close attention to the earnings performance of Hologic in its upcoming release. The company is slated to reveal its earnings on February 5, 2025. The company is expected to report EPS of $1.01, up 3.06% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $1.03 billion, showing a 1.39% escalation compared to the year-ago quarter.
HOLX's full-year Zacks Consensus Estimates are calling for earnings of $4.27 per share and revenue of $4.17 billion. These results would represent year-over-year changes of +4.66% and +3.48%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Hologic. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.31% lower. Hologic currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Hologic has a Forward P/E ratio of 16.47 right now. This represents a discount compared to its industry's average Forward P/E of 28.55.
It's also important to note that HOLX currently trades at a PEG ratio of 2.4. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.26 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 60, which puts it in the top 24% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HOLX in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Hologic (HOLX) Outpaced the Stock Market Today
Hologic (HOLX - Free Report) closed at $71.19 in the latest trading session, marking a +1.17% move from the prior day. This change outpaced the S&P 500's 0.61% gain on the day. Meanwhile, the Dow gained 0.3%, and the Nasdaq, a tech-heavy index, added 1.28%.
The medical device maker's stock has dropped by 3.18% in the past month, falling short of the Medical sector's gain of 1.64% and the S&P 500's gain of 2.08%.
The investment community will be paying close attention to the earnings performance of Hologic in its upcoming release. The company is slated to reveal its earnings on February 5, 2025. The company is expected to report EPS of $1.01, up 3.06% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $1.03 billion, showing a 1.39% escalation compared to the year-ago quarter.
HOLX's full-year Zacks Consensus Estimates are calling for earnings of $4.27 per share and revenue of $4.17 billion. These results would represent year-over-year changes of +4.66% and +3.48%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Hologic. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.31% lower. Hologic currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Hologic has a Forward P/E ratio of 16.47 right now. This represents a discount compared to its industry's average Forward P/E of 28.55.
It's also important to note that HOLX currently trades at a PEG ratio of 2.4. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.26 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 60, which puts it in the top 24% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HOLX in the coming trading sessions, be sure to utilize Zacks.com.